MEDAFOR
Medafor, Inc. is a medical device company that has developed and commercialized a patented hemostatic agent that has been shown to enhance and accelerate the normal blood clotting process. Medafor’s MPH technology is unparalleled in terms of safety, efficacy, and cost.
MEDAFOR
Social Links:
Industry:
Biotechnology Medical Medical Device
Founded:
1999-01-01
Address:
Minneapolis, Minnesota, United States
Country:
United States
Website Url:
http://www.medafor.com
Total Employee:
51+
Status:
Closed
Contact:
7635711035
Total Funding:
115 K USD
Technology used in webpage:
Domain Not Resolving HostMySite
Similar Organizations
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Tarsa Therapeutics
Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.
Current Employees Featured
Founder
Official Site Inspections
http://www.medafor.com
- Host name: 204.12.99.109
- IP address: 204.12.99.109
- Location: Newark United States
- Latitude: 39.6327
- Longitude: -75.6998
- Metro Code: 504
- Timezone: America/New_York
- Postal: 19702
More informations about "Medafor"
Medafor - Crunchbase Company Profile & Funding
Medafor, Inc. is a medical device company that has developed and commercialized a patented hemostatic agent that has been shown to enhance and accelerate the normal blood clotting …See details»
Medafor Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Medafor. Use the PitchBook Platform to explore the full profile.See details»
Medafor Inc. - LinkedIn
Medafor, Inc. is a medical device company that has developed and commercialized a patented hemostatic agent that has been shown to enhance and accelerate the normal blood clotting process.See details»
Medafor, Inc. Company Profile | Minneapolis, MN | Competitors ...
Find company research, competitor information, contact details & financial data for Medafor, Inc. of Minneapolis, MN. Get the latest business insights from Dun & Bradstreet.See details»
Medafor Inc. Financial Overview, Employee Count, and Competitors
Medafor, Inc. is a medical device company that has developed and commercialized a patented hemostatic agent that has been shown to enhance and accelerate the normal blood clotting …See details»
Medafor Inc - Company Profile and News - Bloomberg Markets
Medafor, Inc. develops, manufactures, and distributes hemostatic agents. The Company produces adjunctive hemostatic devices to assist when control of capillary, venous, and arteriolar …See details»
Medafor - Products, Competitors, Financials, Employees, …
Medafor develops and markets a breakthrough in hemostatic technology and absorbable hemostats called Microporous Polysaccharide Hemospheres (MPH). Use the CB Insights …See details»
Medafor - Funding, Financials, Valuation & Investors - Crunchbase
Medafor develops novel hemostatic technology and absorbable hemostats called MPH (R), which accelerates the normal blood clotting process.See details»
Medafor - Crunchbase
Medafor develops novel hemostatic technology and absorbable hemostats called MPH(R), which accelerates the normal blood clotting process.See details»
Medafor, Inc. - University of Minnesota Twin Cities
Medafor, Inc. 2700 Freeway Boulevard Suite 800 Minneapolis, MN 55430 Phone: (763) 571-6300 FAX: (763) 571-1035 E-mail: [email protected] Contact: Richard Zerban, Director and …See details»
CryoLife to Receive Approximately $15.1 Million from Acquisition …
Oct 7, 2013 · Medafor develops and markets hemostatic technology and absorbable hemostats. Steven G. Anderson, chairman, president and CEO of CryoLife, said, "We are pleased that our …See details»
Medafor Company Profile -Sales, Contacts, Competitors – Buzzfile
Medafor, Inc. (trade name Medafor) is in the Bandages and Dressings business. View competitors, revenue, employees, website and phone number.See details»
C.R. Bard to Acquire Medafor, Inc. for $200 Million - BioSpace
Aug 19, 2013 · MURRAY HILL, N.J.--(BUSINESS WIRE)-- C. R. Bard, Inc. (BCR) today announced that it has entered into a definitive agreement to acquire privately-held Medafor, …See details»
CryoLife Becomes Largest Shareowner of Medafor, Inc. and …
Jan 13, 2010 · Medafor shareholders can find additional information about CryoLife and its proposal to acquire Medafor at www.cryolife.com/medaforoffer. The full text of CryoLife's most …See details»
Davol Inc. completed the acquisition of Medafor, Inc. from …
Oct 1, 2013 · Davol Inc. entered into a definitive agreement to acquire Medafor, Inc. from CryoLife Inc. and other shareholders for $280 million on August 19, 2013. Under the terms of the …See details»
Medafor - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Medafor develops novel hemostatic technology and absorbable hemostats called MPH(R), which accelerates the normal blood clotting process.See details»
Medafor of Brooklyn Center is sold to unit of C.R. Bard - Star Tribune
Aug 20, 2013 · Medafor of Brooklyn Center agreed to be purchased by a unit of C.R. Bard for $200 million plus revenue-based incentives. Medafor had previously fought off takeover …See details»
FDA Approves Medafor's Arista(TM) AH Absorbable Surgical
Oct 24, 2006 · MINNEAPOLIS, Oct. 3-- Medafor, Inc. announced today that its Arista (TM) AH Absorbable Hemostat has received FDA approval to be marketed within the United States. …See details»
Bard grabs Medafor for $200M, diving deep into the blood …
Aug 19, 2013 · C.R. Bard dove deep into the blood-clotting business this week, announcing plans to snatch up Minnesota-based Medafor in a deal worth at least $200 million.See details»
Medafor - Contacts, Employees, Board Members, Advisors & Alumni
Medafor develops novel hemostatic technology and absorbable hemostats called MPH(R), which accelerates the normal blood clotting process.See details»